Literature DB >> 17082588

CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.

Changwan Hong1, Hyunji Lee, Mihwa Oh, Chang-Yuil Kang, Seokmann Hong, Se-Ho Park.   

Abstract

NKT cells perform crucial roles in tumor surveillance, functioning as regulators of early host response. In this study, we have assessed the effects of NKT activation at the time of tumor Ag immunization, and have evaluated the contributions of CD4+ and CD8+ T cells in tumor rejection during adaptive immune response against live tumor cells. Our data indicate that CD4+ T cells play critical roles, not only in assisting CTL, but also in the orchestration of host response against the tumor. The CD4+ T cells were found to reject the transplanted tumor cells very efficiently under conditions in which the CTLs were removed either genetically, or via the action of anti-CD8 Ab in mice that had been immunized with tumor extracts and alpha-galactosylceramide. Immunization resulted in an NKT cell-dependent antitumor adaptive immune response, which was associated with both CD4+ T cells and cytokine IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082588     DOI: 10.4049/jimmunol.177.10.6747

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator.

Authors:  Sveinung W Sorbye; Thomas Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Anti-tumor immunostimulatory effect of heat-killed tumor cells.

Authors:  Taek Joon Yoon; Ji Yeon Kim; Hyojeong Kim; Changwan Hong; Hyunji Lee; Chang Kwon Lee; Kwang Ho Lee; Seokmann Hong; Se Ho Park
Journal:  Exp Mol Med       Date:  2008-02-29       Impact factor: 8.718

3.  An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.

Authors:  Yeonseok Chung; Hong Qin; Chang-Yuil Kang; Sanghee Kim; Larry W Kwak; Chen Dong
Journal:  Blood       Date:  2007-06-20       Impact factor: 22.113

4.  Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  BMC Clin Pathol       Date:  2012-02-29

5.  Prognostic impact of lymphocytes in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

6.  Invariant NKT cells act as an adjuvant to enhance Th2 inflammatory response in an OVA-induced mouse model of asthma.

Authors:  Hanxiang Nie; Qiaoyu Yang; Guqin Zhang; Ailing Wang; Qing He; Min Liu; Ping Li; Jiong Yang; Yi Huang; Xuhong Ding; Hongying Yu; Suping Hu
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

7.  Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette.

Authors:  John P Driver; Felix Scheuplein; Yi-Guang Chen; Alexandra E Grier; S Brian Wilson; David V Serreze
Journal:  Diabetes       Date:  2009-11-10       Impact factor: 9.461

8.  Using magnetic resonance imaging to evaluate dendritic cell-based vaccination.

Authors:  Peter M Ferguson; Angela Slocombe; Richard D Tilley; Ian F Hermans
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

9.  Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.

Authors:  Martin K Hunn; Ian F Hermans
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

10.  B Cells Promote Th1- Skewed NKT Cell Response by CD1d-TCR Interaction.

Authors:  Jung Hoon Shin; Se-Ho Park
Journal:  Immune Netw       Date:  2013-10-26       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.